"10.1371_journal.pone.0075416","plos one","2013-10-09T00:00:00Z","Ellen M Mowry; Robert F Carey; Maria R Blasco; Jean Pelletier; Pierre Duquette; Pablo Villoslada; Irina Malikova; Elaine Roger; R Phillip Kinkel; Jamie McDonald; Peter Bacchetti; Emmanuelle Waubant","Multiple Sclerosis Center, Department of Neurology, Johns Hopkins University, Baltimore, Maryland, United States of America; Multiple Sclerosis Center, Department of Neurology, University of California San Francisco, San Francisco, California, United States of America; Department of Neurology, Hospital Universitario Puerta de Hierro, Madrid, Spain; Pole de Neurosciences Cliniques, Service de Neurologie, Centre de Résonance Magnétique Biologique et Médicale, Centre Hospitalier Universitaire Timone, Aix Marseille Université, Marseille, France; Multiple Sclerosis Clinic, Centre Hospitalier de L′Universite de Montreal, Montreal, Canada; Center of Neuroimmunology, Institute of Biomedical Research August Pi Sunyer-Hospital Clinic, Barcelona, Spain; Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States of America; Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, United States of America","Conceived and designed the experiments: EMM PB EW. Performed the experiments: EMM PB EW. Analyzed the data: EMM PB EW. Contributed reagents/materials/analysis tools: EMM RFC MRB JP PD PV IM ER RPK JM EW. Wrote the paper: EMM PB EW. Critical revisions to article: EMM RFC MRB JP PD PV IM ER RPK JM PB EW.","The authors have read the journals policy and have the following conflicts: Dr. Mowry has received free medication from Teva Pharmaceuticals for an investigator-initiated clinical trial, of which she is Principal Investigator. Dr Pelletier has participated in Advisory Committees for several companies (Merck Serono, Bayer Schering, Biogen Idec, Sanofi Aventis, Teva, Novartis). He has received unrestricted research grants from Biogen Idec, Merck Serono, Bayer Schering, Novartis, and Sanofi Aventis. Dr. Duquette has participated in Advisory committees for several companies (Berlex, Biogen Idec, Serono, Novartis, and Teva Neurosciences) in the MS field and has been supported to attend MS meetings by the same companies. He has a research grant for an investigator-initiated study from Biogen Idec. Dr. Villoslada received consulting fees from Roche, Novartis, MedImmune, Neutotech Pharma, and Digna Biotech and is founder and holds stocks in Bionure Farma. Dr Kinkel has received honoraria as a consultant for Biogen Idec, Teva, Genzyme and Novartis. He has received research support from Biogen Idec. Dr. Waubant has received honoraria from Biogen Idec for 2 educational programs, and from Roche and Actelion as an ad-hoc consultant. She has received research support from Biogen Idec and Sanofi Aventis in the form of free medications for an ongoing trial. Co-author Pablo Villoslada is a PLOS ONE Editorial Board member. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials.","2013","10","Ellen M Mowry","EMM",12,TRUE,3,3,3,3,TRUE,TRUE,FALSE,0,NA,FALSE
